Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today we look at what some people in the industry are calling a “pharm to table” trend. Read on to learn more about it. Viking oral obesity pill study results disappoint From…
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01. A new oral weight loss drug developed by Viking Therapeutics hit the mark in a…
Among the demands that President Trump has made to the pharmaceutical industry to lower drug prices, there’s been one that companies have enthusiastically supported: selling drugs directly to consumers. Even before Trump began discussing the idea, Eli Lilly and Novo Nordisk had adopted this model for their blockbuster weight loss treatments — offering discounted cash…
Conflicts of interest on federal government vaccine panels have been declining to “historically low levels” in recent years, according to a new study, whose findings are likely to increase debate over a contentious issue pushed by Health and Human Services Secretary Robert F. Kennedy Jr. The rate of conflicts found among members of the Centers…
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09. This is the online version of STAT’s weekly…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we examine the plush pay packages of health care’s top CEOs in 2024. Also, we discuss Stealth BioTherapeutics’ efforts to rally support behind its Barth syndrome drug, and hear more from the…
In a highly unusual move, a small biotech company has disclosed a rejection letter from the Food and Drug Administration in hopes of rallying support for regulatory approval of an ultra-rare disease drug. The step is part of a campaign being pursued by Stealth BioTherapeutics in light of its seesaw experience with the agency over…
The top executives running the health care industry’s blue-chip companies amassed generational wealth in 2024, even as many businesses slipped in the eyes of their investors. Health care remains a highly profitable industry. But the biggest companies didn’t meet the lofty expectations of shareholders, dragging down their stocks. A few CEOs lost their jobs as…
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we see march-in rights return to the headlines, ponder how Eli Lilly’s plan to hike list prices in Europe may play out, and more. Trump administration puts focus on march-in rights The…
